1
|
Wang H, Ishchenko A, Skudlarek J, Shen P, Dzhekieva L, Painter RE, Chen YT, Bukhtiyarova M, Leithead A, Tracy R, Babaoglu K, Bahnck-Teets C, Buevich A, Cabalu TD, Labroli M, Lange H, Lei Y, Li W, Liu J, Mann PA, Meng T, Mitchell HJ, Mulhearn J, Scapin G, Sha D, Shaw AW, Si Q, Tong L, Wu C, Wu Z, Xiao JC, Xu M, Zhang LK, McKenney D, Miller RR, Black TA, Cooke A, Balibar CJ, Klein DJ, Raheem I, Walker SS. Cerastecins inhibit membrane lipooligosaccharide transport in drug-resistant Acinetobacter baumannii. Nat Microbiol 2024:10.1038/s41564-024-01667-0. [PMID: 38649414 DOI: 10.1038/s41564-024-01667-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Accepted: 03/06/2024] [Indexed: 04/25/2024]
Abstract
Carbapenem-resistant Acinetobacter baumannii infections have limited treatment options. Synthesis, transport and placement of lipopolysaccharide or lipooligosaccharide (LOS) in the outer membrane of Gram-negative bacteria are important for bacterial virulence and survival. Here we describe the cerastecins, inhibitors of the A. baumannii transporter MsbA, an LOS flippase. These molecules are potent and bactericidal against A. baumannii, including clinical carbapenem-resistant Acinetobacter baumannii isolates. Using cryo-electron microscopy and biochemical analysis, we show that the cerastecins adopt a serpentine configuration in the central vault of the MsbA dimer, stalling the enzyme and uncoupling ATP hydrolysis from substrate flipping. A derivative with optimized potency and pharmacokinetic properties showed efficacy in murine models of bloodstream or pulmonary A. baumannii infection. While resistance development is inevitable, targeting a clinically unexploited mechanism avoids existing antibiotic resistance mechanisms. Although clinical validation of LOS transport remains undetermined, the cerastecins may open a path to narrow-spectrum treatment modalities for important nosocomial infections.
Collapse
Affiliation(s)
- Hao Wang
- Merck & Co., Inc., West Point, PA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Ying Lei
- Merck & Co., Inc., West Point, PA, USA
| | - Wei Li
- Merck & Co., Inc., West Point, PA, USA
| | - Jian Liu
- Merck & Co., Inc., West Point, PA, USA
| | | | - Tao Meng
- Merck & Co., Inc., Rahway, NJ, USA
| | | | | | | | - Deyou Sha
- Merck & Co., Inc., West Point, PA, USA
| | | | - Qian Si
- Merck & Co., Inc., West Point, PA, USA
| | - Ling Tong
- Merck & Co., Inc., West Point, PA, USA
| | | | - Zhe Wu
- Merck & Co., Inc., West Point, PA, USA
| | | | - Min Xu
- Merck & Co., Inc., West Point, PA, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Liu W, Mulhearn J, Hao B, Cañellas S, Last S, Gómez JE, Jones A, De Vera A, Kumar K, Rodríguez R, Van Eynde L, Strambeanu II, Wolkenberg SE. Enabling Deoxygenative C(sp 2)-C(sp 3) Cross-Coupling for Parallel Medicinal Chemistry. ACS Med Chem Lett 2023; 14:853-859. [PMID: 37312855 PMCID: PMC10258906 DOI: 10.1021/acsmedchemlett.3c00118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Accepted: 05/10/2023] [Indexed: 06/15/2023] Open
Abstract
Herein we report the development of an automated deoxygenative C(sp2)-C(sp3) coupling of aryl bromide with alcohols to enable parallel medicinal chemistry. Alcohols are among the most diverse and abundant building blocks, but their usage as alkyl precursors has been limited. Although metallaphotoredox deoxygenative coupling is becoming a promising strategy to form C(sp2)-C(sp3) bond, the reaction setup limits its widespread application in library synthesis. To achieve high throughput and consistency, an automated workflow involving solid-dosing and liquid-handling robots has been developed. We have successfully demonstrated this high-throughput protocol is robust and consistent across three automation platforms. Furthermore, guided by cheminformatic analysis, we examined alcohols with comprehensive chemical space coverage and established a meaningful scope for medicinal chemistry applications. By accessing the rich diversity of alcohols, this automated protocol has the potential to substantially increase the impact of C(sp2)-C(sp3) cross-coupling in drug discovery.
Collapse
Affiliation(s)
- Wei Liu
- Discovery
Chemistry, Janssen Research & Development
LLC, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - James Mulhearn
- Discovery
Chemistry, Janssen Research & Development
LLC, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Bo Hao
- Discovery
Chemistry, Janssen Research & Development
LLC, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Santiago Cañellas
- Discovery
Chemistry, Janssen Research & Development LLC, Janssen-Cilag, S.A., E-45007 Toledo, Spain
| | - Stefaan Last
- Discovery
Chemistry, Janssen Research & Development
LLC, 2340 Beerse, Belgium
| | - José Enrique Gómez
- Discovery
Chemistry, Janssen Research & Development LLC, Janssen-Cilag, S.A., E-45007 Toledo, Spain
| | - Alexander Jones
- Discovery
Chemistry, Janssen Research & Development
LLC, 2340 Beerse, Belgium
| | - Alexander De Vera
- Discovery
Chemistry, Janssen Research & Development
LLC, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Kiran Kumar
- Discovery
Chemistry, Janssen Research & Development
LLC, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Raquel Rodríguez
- Discovery
Chemistry, Janssen Research & Development LLC, Janssen-Cilag, S.A., E-45007 Toledo, Spain
| | - Lars Van Eynde
- Discovery
Chemistry, Janssen Research & Development
LLC, 2340 Beerse, Belgium
| | - Iulia I. Strambeanu
- Discovery
Chemistry, Janssen Research & Development
LLC, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| | - Scott E. Wolkenberg
- Discovery
Chemistry, Janssen Research & Development
LLC, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
| |
Collapse
|
3
|
Cosden M, Jinn S, Yao L, Gretzula CA, Kandebo M, Toolan D, Hatcher NG, Ma L, Lemaire W, Adam GC, Burlein C, Minnick C, Flick R, Watt ML, Mulhearn J, Fraley M, Drolet RE, Marcus JN, Smith SM. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiol Dis 2021; 159:105507. [PMID: 34509608 DOI: 10.1016/j.nbd.2021.105507] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 08/26/2021] [Accepted: 09/07/2021] [Indexed: 11/16/2022] Open
Abstract
Mutations in the lysosomal enzyme glucocerebrosidase (GCase, GBA1 gene) are the most common genetic risk factor for developing Parkinson's disease (PD). GCase metabolizes the glycosphingolipids glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph). Mutations in GBA1 reduce enzyme activity and the resulting accumulation of glycosphingolipids may contribute to the underlying pathology of PD, possibly via altering lysosomal function. While reduction of GCase activity exacerbates α-synuclein (α-syn) aggregation, it has not been determined that this effect is the result of altered glycosphingolipid levels and lysosome function or some other effect of altering GCase. The glycosphingolipid GlcCer is synthesized by a single enzyme, glucosylceramide synthase (GCS), and small molecule inhibitors (GCSi) reduce cellular glycosphingolipid levels. In the present studies, we utilize a preformed fibril (PFF) rodent primary neuron in vitro model of α-syn pathology to investigate the relationship between glycosphingolipid levels, α-syn pathology, and lysosomal function. In primary cultures, pharmacological inhibition of GCase and D409V GBA1 mutation enhanced accumulation of glycosphingolipids and insoluble phosphorylated α-syn. Administration of a novel small molecule GCSi, benzoxazole 1 (BZ1), significantly decreased glycosphingolipid concentrations in rodent primary neurons and reduced α-syn pathology. BZ1 rescued lysosomal deficits associated with the D409V GBA1 mutation and α-syn PFF administration, and attenuated α-syn induced neurodegeneration of dopamine neurons. In vivo studies revealed BZ1 had pharmacological activity and reduced glycosphingolipids in the mouse brain to a similar extent observed in neuronal cultures. These data support the hypothesis that reduction of glycosphingolipids through GCS inhibition may impact progression of synucleinopathy and BZ1 is useful tool to further examine this important biology.
Collapse
Affiliation(s)
- Mali Cosden
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Sarah Jinn
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Lihang Yao
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Cheryl A Gretzula
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Monika Kandebo
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Dawn Toolan
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Nathan G Hatcher
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Lei Ma
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Wei Lemaire
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - Gregory C Adam
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - Christine Burlein
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - Christina Minnick
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - Rose Flick
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - Marla L Watt
- Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, United States
| | - James Mulhearn
- Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, United States
| | - Mark Fraley
- Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, United States
| | - Robert E Drolet
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Jacob N Marcus
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States
| | - Sean M Smith
- Neuroscience Discovery, Merck & Co., Inc., West Point, PA 19486, United States.
| |
Collapse
|
4
|
Tong L, Li W, Lo MMC, Gao X, Wai JMC, Rudd M, Tellers D, Joshi A, Zeng Z, Miller P, Salinas C, Riffel K, Haley H, Purcell M, Holahan M, Gantert L, Schubert JW, Jones K, Mulhearn J, Egbertson M, Meng Z, Hanney B, Gomez R, Harrison ST, McQuade P, Bueters T, Uslaner J, Morrow J, Thomson F, Kong J, Liao J, Selyutin O, Bao J, Hastings NB, Agrawal S, Magliaro BC, Monsma FJ, Smith MD, Risso S, Hesk D, Hostetler E, Mazzola R. Discovery of [ 11C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases. J Med Chem 2020; 63:2411-2425. [PMID: 32101422 DOI: 10.1021/acs.jmedchem.9b01406] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The measurement of receptor occupancy (RO) using positron emission tomography (PET) has been instrumental in guiding discovery and development of CNS directed therapeutics. We and others have investigated muscarinic acetylcholine receptor 4 (M4) positive allosteric modulators (PAMs) for the treatment of symptoms associated with neuropsychiatric disorders. In this article, we describe the synthesis, in vitro, and in vivo characterization of a series of central pyridine-related M4 PAMs that can be conveniently radiolabeled with carbon-11 as PET tracers for the in vivo imaging of an allosteric binding site of the M4 receptor. We first demonstrated its feasibility by mapping the receptor distribution in mouse brain and confirming that a lead molecule 1 binds selectively to the receptor only in the presence of the orthosteric agonist carbachol. Through a competitive binding affinity assay and a number of physiochemical properties filters, several related compounds were identified as candidates for in vivo evaluation. These candidates were then radiolabeled with 11C and studied in vivo in rhesus monkeys. This research eventually led to the discovery of the clinical radiotracer candidate [11C]MK-6884.
Collapse
Affiliation(s)
- Ling Tong
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Wenping Li
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Michael Man-Chu Lo
- Discovery Chemistry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xiaolei Gao
- Discovery Chemistry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jenny Miu-Chen Wai
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Michael Rudd
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - David Tellers
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Aniket Joshi
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Zhizhen Zeng
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Patricia Miller
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Cristian Salinas
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Kerry Riffel
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Hyking Haley
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Mona Purcell
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Marie Holahan
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Liza Gantert
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Jeffrey W Schubert
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Kristen Jones
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - James Mulhearn
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Melissa Egbertson
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Zhaoyang Meng
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Barbara Hanney
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Robert Gomez
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Scott T Harrison
- Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Paul McQuade
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Tjerk Bueters
- Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Jason Uslaner
- Discovery Biology, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - John Morrow
- Discovery Biology, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Fiona Thomson
- Discovery Biology, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Jongrock Kong
- Department of Process Research and Development, Merck & Co., Inc., 126 East Lincoln Avenue Rahway, New Jersey 07065, United States
| | - Jing Liao
- Department of Process Research and Development, Merck & Co., Inc., 126 East Lincoln Avenue Rahway, New Jersey 07065, United States
| | - Oleg Selyutin
- Discovery Chemistry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jianming Bao
- Discovery Chemistry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Nicholas B Hastings
- Discovery Biology, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Sony Agrawal
- Discovery Biology, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Brian C Magliaro
- Discovery Biology, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Frederick J Monsma
- Discovery Biology, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Michelle D Smith
- Discovery Biology, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Stefania Risso
- Discovery Biology, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - David Hesk
- Department of Process Research and Development, Merck & Co., Inc., 126 East Lincoln Avenue Rahway, New Jersey 07065, United States
| | - Eric Hostetler
- Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Robert Mazzola
- Discovery Chemistry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
5
|
Schubert JW, Harrison ST, Mulhearn J, Gomez R, Tynebor R, Jones K, Bunda J, Hanney B, Wai JM, Cox C, McCauley JA, Sanders JM, Magliaro B, O'Brien J, Pajkovic N, Huszar Agrapides SL, Taylor A, Gotter A, Smith SM, Uslaner J, Browne S, Risso S, Egbertson M. Discovery, Optimization, and Biological Characterization of 2,3,6‐Trisubstituted Pyridine‐Containing M
4
Positive Allosteric Modulators. ChemMedChem 2019; 14:943-951. [PMID: 30920765 DOI: 10.1002/cmdc.201900088] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Indexed: 11/08/2022]
Affiliation(s)
| | - Scott T. Harrison
- Department of Medicinal ChemistryMerck & Co., Inc. West Point PA USA
| | - James Mulhearn
- Department of Medicinal ChemistryMerck & Co., Inc. West Point PA USA
| | - Robert Gomez
- Department of Medicinal ChemistryMerck & Co., Inc. West Point PA USA
| | - Robert Tynebor
- Department of Medicinal ChemistryMerck & Co., Inc. West Point PA USA
| | - Kristen Jones
- Department of Medicinal ChemistryMerck & Co., Inc. West Point PA USA
| | - Jaime Bunda
- Department of Medicinal ChemistryMerck & Co., Inc. West Point PA USA
| | - Barbara Hanney
- Department of Medicinal ChemistryMerck & Co., Inc. West Point PA USA
| | | | - Chris Cox
- Department of Medicinal ChemistryMerck & Co., Inc. West Point PA USA
| | - John A. McCauley
- Department of Medicinal ChemistryMerck & Co., Inc. West Point PA USA
| | - John M. Sanders
- Department of Computational and Structural ChemistryMerck & Co., Inc. West Point PA USA
| | - Brian Magliaro
- Department of In Vitro PharmacologyMerck & Co., Inc. West Point PA USA
| | - Julie O'Brien
- Department of In Vitro PharmacologyMerck & Co., Inc. West Point PA USA
| | - Natasa Pajkovic
- Department of Pharmacokinetics, Pharmacodynamics, and Drug MetabolismMerck & Co., Inc West Point PA USA
| | | | - Anne Taylor
- Department of In Vivo PharmacologyMerck & Co., Inc. West Point PA USA
| | - Anthony Gotter
- Department of Neuroscience ResearchMerck & Co., Inc. West Point PA USA
| | - Sean M. Smith
- Department of Neuroscience ResearchMerck & Co., Inc. West Point PA USA
| | - Jason Uslaner
- Department of Neuroscience ResearchMerck & Co., Inc. West Point PA USA
| | - Susan Browne
- Department of In Vivo PharmacologyMerck & Co., Inc. West Point PA USA
| | - Stefania Risso
- Department of Neuroscience ResearchMerck & Co., Inc. West Point PA USA
| | - Melissa Egbertson
- Department of Medicinal ChemistryMerck & Co., Inc. West Point PA USA
| |
Collapse
|
6
|
Zeng Z, Miller PJ, Connolly BM, O'Malley SS, Lohith T, Bennacef I, Mulhearn J, Schenk DJ, Hesk D, Walji A, Sur C, Li W, Hostetler ED, Evelhoch J. [IC‐P‐207]: IN VITRO BINDING STUDIES TO EVALUATE THE NFT‐SPECIFICITY OF [
3
H]MK‐6240 AND [
3
H]AV‐1451 BINDING IN SUBCORTICAL REGIONS OF THE HUMAN AD BRAIN. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.2583] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Zhizhen Zeng
- Merck & Co.Inc., Translational Biomarkers, West PointPAUSA
| | | | | | | | - Talakad Lohith
- Merck & Co.Inc., Translational Biomarkers, West PointPAUSA
| | | | | | | | - David Hesk
- Merck & Co., Inc., Labeled Compound SynthesisRahwayNJUSA
| | - Abbas Walji
- Merck & Co. Inc.Exploratory Chemistry, West PointPAUSA
| | - Cyrille Sur
- Merck & Co.Inc., Translational Biomarkers, West PointPAUSA
| | - Wenping Li
- Merck & Co.Inc., Translational Biomarkers, West PointPAUSA
| | | | | |
Collapse
|
7
|
Zeng Z, Miller PJ, Connolly BM, O'Malley SS, Lohith T, Mulhearn J, Bennacef I, Walji A, Schenk DJ, Hesk D, Sur C, Li W, Hostetler ED, Evelhoch J. [P4–055]: IN VITRO BINDING STUDIES TO EVALUATE THE NFT‐SPECIFICITY OF [
3
H]MK‐6240 AND [
3
H]AV‐1451 BINDING IN SUBCORTICAL REGIONS OF HUMAN AD BRAIN. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.1920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Zhizhen Zeng
- Merck & Co.Inc./Translational Biomarkers, West PointPAUSA
| | | | | | | | - Talakad Lohith
- Merck & Co.Inc./Translational Biomarkers, West PointPAUSA
| | | | | | - Abbas Walji
- Merck & Co. Inc. / Exploratory ChemistryWest PointPAUSA
| | | | - David Hesk
- Merck & Co., Inc./Labeled Compound SynthesisRahwayNJUSA
| | - Cyrille Sur
- Merck & Co.Inc./Translational Biomarkers, West PointPAUSA
| | - Wenping Li
- Merck & Co.Inc./Translational Biomarkers, West PointPAUSA
| | | | | |
Collapse
|
8
|
Zeng Z, Miller PJ, Connolly BM, O’Malley SS, Bennacef I, Mulhearn J, David SJ, Hesk D, Soriano A, Abbas W, Eric HD. P1‐244: Comparing [
3
H]MK‐6240 and [
3
H]AV‐1451(T‐807) in
in VITRO
Binding Studies in Brain Tissues. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Zhizhen Zeng
- Merck & Co. / Translational BiomarkersWest PointPA USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Zeng Z, Miller PJ, Connolly BM, O’Malley SS, Bennacef I, Mulhearn J, Schenk DJ, Hesk D, Soriano A, Abbas W, Hostetler ED. IC‐P‐199: Comparing [
3
H]MK‐6240 and [
3
H]AV‐1451(T‐807) In
In vitro
Binding Studies in Brain Tissues. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Zhizhen Zeng
- Merck & Co./Translational BiomarkersWest PointPA USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Hostetler ED, Sanabria-Bohórquez S, Fan H, Zeng Z, Gammage L, Miller P, O'Malley S, Connolly B, Mulhearn J, Harrison ST, Wolkenberg SE, Barrow JC, Williams DL, Hargreaves RJ, Sur C, Cook JJ. [18F]Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey. Nucl Med Biol 2011; 38:1193-203. [DOI: 10.1016/j.nucmedbio.2011.04.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2011] [Revised: 03/22/2011] [Accepted: 04/13/2011] [Indexed: 12/28/2022]
|
11
|
Harrison ST, Mulhearn J, Wolkenberg SE, Miller PJ, O’Malley SS, Zeng Z, Williams DL, Hostetler ED, Sanabria-Bohórquez S, Gammage L, Fan H, Sur C, Culberson JC, Hargreaves RJ, Cook JJ, Hartman GD, Barrow JC. Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328. ACS Med Chem Lett 2011; 2:498-502. [PMID: 24900338 DOI: 10.1021/ml200018n] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2011] [Accepted: 03/15/2011] [Indexed: 11/29/2022] Open
Abstract
5-Fluoro-2-aryloxazolo[5,4-b]pyridines were synthesized and investigated as potential (18)F containing β-amyloid PET ligands. In competition binding assays using human AD brain homogenates, compounds 14b, 16b, and 17b were identified as having favorable potency versus human β-amyloid plaque and were radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. These studies led to the identification of 17b (MK-3328) as a candidate PET ligand for the clinical assessment of β-amyloid plaque load.
Collapse
Affiliation(s)
- Scott T. Harrison
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - James Mulhearn
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Scott E. Wolkenberg
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Patricia J. Miller
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Stacey S. O’Malley
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Zhizhen Zeng
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - David L. Williams
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Eric D. Hostetler
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Sandra Sanabria-Bohórquez
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Linda Gammage
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Hong Fan
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Cyrille Sur
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - J. Christopher Culberson
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Richard J. Hargreaves
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - Jacquelynn J. Cook
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - George D. Hartman
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| | - James C. Barrow
- Departments of Medicinal Chemistry, ‡Imaging, and §Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc., P.O. Box 4, West Point, Pennsylvania 19486, United States
| |
Collapse
|
12
|
Abstract
The Veterans Administration's (VA) Department of Medicine and Surgery, the largest of the civilian federal health care systems, is under continuous White House, congressional, and public pressure to provide greater accountability and increased cost-effectiveness for its $5 billion-plus annual budget. Responding to these pressures, the VA is evaluating in ten of its 172 medical centers a new system of resource allocation and financial management known as a multilevel care system. This is a major VA intiative with highly important implications for both the VA and the private health care sector.
Collapse
|